In human patients, SCA3 pathology is not limited to the CNS; peripheral neuropathy affects up to 60% of patients with SCA3 (França et al., 2009; Durr et al., 1996; McLoughlin et al., 2020). Here, ATXN3 is linked to peripheral neuropathy.